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The glycogen-binding (G) subunit of protein phosphatase-lo is phosphorylated stoichiometrically by glycogen synthase 
kinase-3 (GSK3), and with a greater catalytic efficiency than glycogen synthase, but only after prior phosphorylation 
by cyclic AMP-dependent protein kinase (A-kinase) at site 1. The residues phosphorylated are the first two serines in 
the sequence AIFKPGFSPQPSRRGS-, while the C-terminal serine (site I) is one of the two residues phosphorylated 
by A-kinase. These findings demonstrate that (i) the G subunit undergoes multisite phosphorylation in vitro; (ii) phos- 
phorylation by GSK3 requires the presence of a C-terminal phosphoserine residue; (iii) GSK3 can synergise with protein 
kinases other than casein kinase-2. 
Protein kinase; Protein phosphatase; cyclic AMP; Glycogen metabolism; Glycogen synthase 
1. INTRODUCTION 
Insulin stimulates glycogen synthesis within 
minutes in mammalian skeletal muscle by pro- 
moting the dephosphorylation and activation of 
glycogen synthase, the rate limiting enzyme in this 
process. Phosphate is released relatively specifical- 
ly from a region containing several serine residues 
(the ‘sites 3 region’) which are phosphorylated by 
glycogen synthase kinase-3 (GSK3) [ 11. Interaction 
of insulin with its receptor should therefore lead to 
inhibition of GSK3 and/or to activation of the 
phosphatase(s) acting on the sites 3 region. 
Protein phosphatase-1 (PP-1) and protein 
phosphatase-2A (PP-2A) account for all the 
phosphatase activity in mammalian skeletal muscle 
extracts towards the sites 3 region of glycogen syn- 
thase [2,3]. Two lines of evidence suggest that 
PP-1 is the enzyme that dephosphorylates these 
serines in vivo. Firstly, it accounts for 70% of the 
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glycogen synthase phosphatase activity when mus- 
cle extracts are assayed under standard conditions 
[3]. Secondly, like glycogen synthase, PP-1 is 
specifically associated with glycogen-protein par- 
ticles, whereas PP-2A is not [3,4]. 
The glycogen-associated form of PP-1 (PP-1~) 
is a heterodimer composed of the phosphatase 
catalytic (C) subunit and a glycogen-binding (G) 
subunit [5]. The G subunit is phosphorylated in 
vitro by cyclic AMP-dependent protein kinase (A- 
kinase) at two serines (site 1 and site 2) ([6], fig. l), 
which are 19 residues apart in the primary struc- 
ture [7]. Site 1 is phosphorylated in vivo and 
phosphorylation increases from 0.57 to 
0.83 mol/mol in response to adrenalin [8]. The in 
vivo phosphorylation state of site 2 is unknown. 
Phosphorylation of the G subunit by A-kinase in 
vitro [7], or injection of adrenalin in vivo [8,9], 
promotes dissociation of the C subunit and its 
translocation from the glycogen-protein particles 
to the cytosol. Released C subunit is much less efr 
fective than glycogen-bound PP-lo in dephos- 
phorylating glycogen synthase at physiological 
ionic strength [7]. Furthermore, released C subunit 
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Fig.1. Phosphorylation sites on the G subunit of PP-lo. Tryptic 
peptide Tl comprises residues l-12 and chymotryptic peptide 
Cl/C2 residues 4-23. The sequences are taken from the present 
study and [7,16]. The figure indicates the residues 
phosphorylated by GSK3, the serines, site 1 (Sl) and site 2 (S2), 
phosphorylated by A-kinase, and the pairs of adjacent arginine 
residues that determine the substrate specificity of A-kinase. 
is likely to be inactivated by inhibitor-l, a cytosolic 
protein which after phosphorylation by A-kinase 
becomes a potent inhibitor of PP-1 (review [4]). 
Inactivation of PP-1 by these two mechanisms may 
account for the increased phosphorylation of the 
sites 3 region and decreased activity of glycogen 
synthase that occurs in response to adrenalin [lo]. 
Phosphorylation of the sites 3 region of 
glycogen synthase by GSK3 and its dephosphoryla- 
tion by PP-lo, raised the question of whether 
PP-lo might itself be phosphorylated by GSK3. In 
this paper, we report that the G subunit of PP-lo 
is an even more effective substrate for GSK3 than 
glycogen synthase, but only if the G subunit is first 
phosphorylated by A-kinase. 
2. MATERIALS AND METHODS 
2.1. Protein preparations 
A-kinase purified from bovine cardiac muscle [11], and 
GSK3 [12] and the glycogen synthase-glycogenin complex 
[13,14] from rabbit skeletal muscle were provided by Dr Carl 
Smythe and Miss Sara Nakielny in this laboratory. PP-lo, com- 
prising the C subunit of PPl complexed to the 103 kDa G’ 
fragment of the G subunit, was purified from rabbit skeletal 
muscle as in [6] with some minor modifications [7]. A peptide 
comprising residues 5-22 of the specific protein inhibitor of A- 
kinase (PKI) [15] was a gift from Dr Bruce Kemp, St Vincent’s 
Institute of Medical Research, Melbourne, Australia. Trypsin 
(treated with tosylphenylchloromethyl ketone) and chymotryp- 
sin (3 times crystallised) were Worthington products, purchased 
from Lorne Laboratories (Reading, England). 
2.2. Phosphorylation of PP-1~ and glycogen synthase 
Incubations were carried out at 30°C. and unless indicated 
otherwise contained 50 mM Tris-HC1 (pH 7.0), 0.1 mM EGTA, 
0.1% (by vol.) 2-mercaptoethanol, 25 mM NaF, PP-lo 
(0.18 mg/ml, 1.3 PM) or glycogen synthase (0.36 mg/ml, 
2.9 pM), A-kinase (10 mu/ml) and/or GSK3 (0.75 mu/ml), 
2mM magnesium acetate and 0.1 mM [y-“P]ATP 
(lo6 cpm/nmol). Reactions were initiated with MgATP and 
stopped by addition of either trichloroacetic acid (TCA) to 5%, 
or (for phosphopeptide isolation) by addition of 0.1 vol. of a 
solution containing 100 mM EDTA, 500 mM NaF and 100 mM 
sodium pyrophosphate, pH 7.0. One unit of GSK3 or A-kinase 
is that amount which catalyses the phosphorylation of 1 rmol 
of glycogen synthase per min in the standard asssay. 
2.3. Generation of phosphopeptides 
Native 32P-labelled PP-lo (2.0 ml, 2.6 nmol) was freed from 
[y-‘*P]ATP by centrifugal ultrafiltration (Centricon 30 from 
Amicon) [7] and incubated for 20 min (trypsin) or 10 min 
(chymotrypsin) under conditions that release site 1 peptides as 
TCA-soluble species [16]. Phosphopeptides were further 
purified and analysed as described in section 3. 
2.4. Other analytical procedures 
Protein concentrations were determined by calorimetric assay 
[17] using bovine serum albumin as standard. In calculating 
phosphorylation stoichiometries, the molecular mass of PP-lo 
was taken as 140 kDa [5] and that of the glycogen synthase- 
glycogenin complex as 124 kDa [14]. Reverse phase 
chromatography of peptides was carried out using a Vydac 
218TP54 Crs column (Phase Separations Group, Hesperia, CA, 
USA) and amino acid sequencing on an Applied Biosystems 
470A gas-phase sequencer equipped with an on-line reverse- 
phase chromatography system for identification of 
phenylthiohydantoin amino acids. 
3. RESULTS 
3.1. Phosphorylation of PP-lo by A-kinase and 
GSK3 
Purified preparations of PP-lo were 
phosphorylated rapidly to a level approaching 
2 mol/mol by A-kinase, but not by GSK3 (fig.2), 
as reported previously [5,6]. However, following 
phosphorylation by A-kinase, PP-lo became an 
excellent substrate for GSK3, phosphorylation 
reaching a plateau within 5 min, and at a 
stoichiometry exceeding 1 .O mol/mol PP-lo 
(fig.2). SDS/polyacrylamide gel electrophoresis 
and autoradiography showed that all the 32P-label 
was incorporated into the G subunit (not shown). 
3.2. Identification of the serine residues 
phosphorylated by GSK3 
PP-lo was phosphorylated by A-kinase using 
unlabelled ATP, and then with GSK3 using 
[y-32P]ATP. Following digestion of native 32P- 
labelled PP-lo with chymotrypsin, 90% of the 32P- 
radioactivity was released as TCA-soluble peptides 
within 10 min. When this material was subjected 
to gel filtration on Sephadex GSO Superfine (120 x 
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Fig.2. Phosphorylation of PP-lo by A-kinase and GSK3. 
PP-lo (1.3 CM) was phosphorylated for 10 min under the 
standard conditions in a 0.1 ml incubation containing either 
10 mu/ml A-kinase (C--O) or 0.75 mu/ml GSK3 (H). 
At the point denoted by arrows, 2.5 ~1 of PKI (0.1 mM) was 
added to both incubations to inhibit the A-kinase. The 
incubation containing A-kinase was divided in two, and one 
half supplemented with 2.5 ~1 of 15 mu/ml GSK3 (H), 
while the other received the same volume of buffer (M). 
Conversely, the original incubation which contained CiSK3 was 
supplemented after 10 min with 5 ~1 of 200 mu/ml A-kinase 
(H). Aliquots were removed at the times indicated and 
analysed for incorporation of “P-radioactivity into protein 
1271. 
1.2 cm) equilibrated in 0.1 M NH4HCO3, 82% of 
the applied radioactivity was recovered in a single 
peak that eluted at the same position (VJ VO = 1.8) 
as the chymotryptic phosphopeptide containing 
site 1 [16]. This material was dried, dissolved in 
0.5% (by vol.) trifluoroacetic acid (TFA), and 
chromatographed on a Cl8 reverse phase column 
equilibrated in 0.1% TFA and developed with an 
acetonitrile gradient. Of the applied 32P- 
radioactivity, 72% was recovered in two peaks, Cl 
and C2, that were incompletely resolved (fig.3A) 
and which eluted at the same position as the 
chymotryptic peptide containing site 1 [16]. The 
amino acid compositions of Cl and C2 (table 1) 
were very similar to that of the site 1 chymotryptic 
peptide. Both had the N-terminal sequence 
KPGFSPQPSRR-, confirming their identity as 
forms of the site 1 chymotryptic peptide (see fig. 1). 
time (min) 
Fig.3. Purification of chymotryptic (A) and tryptic (B) 
phosphopeptides containing the residues phosphorylated by 
GSK3. Reverse phase chromatography was carried out on a 
Vydac Cl8 column using a Gilson HPLC system equipped with 
an on-line radioactivity monitor. The column was equilibrated 
in 0.1 Qo TFA and developed at 1 .O ml/min with an acetonitrile 
gradient (040%) increasing at 0.6% per min. Fractions of 
0.5 ml were collected. 32P-radioactivity is shown by the solid 
line and the acetonitrile gradient by the broken line. The major 
chymotryptic (Cl and C2) and tryptic (Tl) phosphopeptides are 
marked. 
In peptide C2, 32P-radioactivity was stoichio- 
metric with amino acids present as single residues, 
while 32P-radioactivity in peptide Cl was present at 
a stoichiometry near 2.0 (table 1). This indicated 
that Cl and C2 were the same peptide phosphor- 
ylated by GSK3 to 2.0 and 1.0 mol/mol, respec- 
tively. In this case, Cl should be a triphosphor- 
ylated and C2 a diphosphorylated erivative, since 
site 1 had already been phosphorylated by A- 
kinase using unlabelled ATP. Consistent with this 
view, peptide Cl migrated more rapidly to the 
anode than C2 in isoelectric focussing experiments 
(fig.4), while C2 migrated more rapidly than the 
“P-1abelled monophosphorylated chymotryptic 
peptide phosphorylated by A-kinase alone (termed 
peptide C3 in fig.4). 
The Cl phosphopeptide contains four serines in 
addition to site 1. In order to identify which two 
serines were phosphorylated by GSK3, PP-1~ 
phosphorylated by A-kinase using unlabelled ATP 
and then GSK3 using [Y-~~P]ATP, was subjected 
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Table 1 
Amino acid compositions of peptides Cl, C2 and Tl 
Amino acid Cl c2 Tl 
(mol/mol) (mol/mol) (mol/mol) 
Asx 0.7 1.0 _ 
GlX 4.8 (4) 4.6 (4) 1.0 (1) 
Ser 5.0 (5) 4.1 (5) 2.0 (2) 
GlY 2.6 (2) 2.4 (2) 1.1 (1) 
Arg 2.0 (2) 2.0 (2) 1.1 (1) 
Thr 0.6 0.7 - 
Ala 0.7 1.1 1.0 (1) 
Pro 3.5 (3) 2.6 (3) 3.4 (3) 
Tyr 1.4 (1) 1.0 (1) _ 
Val 1.1 (1) 0.8 (1) _ 
Ile _ - 0.8 (1) 
Leu 0.6 0.6 - 
Phe 0.9 (1) 0.6 (I) 1.9 (2) 
LYS 1.3 (1) 1.4 (1) 1.0 (1) 
“P phosphate 1.82 (2) 0.96 (I) 2.06 (2) 
Peptide Cl was the 30.5 min fraction and peptide C2 the 
31.5 min fraction from fig.3. Samples were hydrolysed for 1 h 
at 15O’C in 6 N HCI containing 2 mM phenol, dried, converted 
to phenylthiocarbamyl derivatives and analysed on a Waters 
PICOTAG system. Values for serine, threonine and tyrosine 
were corrected for 17%, 13% and 16% destruction, 
respectively, and values below 0.4 mol are omitted. Numbers in 
parentheses indicate residues determined by sequence analysis 
(161. Peptide Cl/C2 comprises residues 4-23 of the sequence 
Fig.4. Isoelectric focussing of chymotryptic phosphopeptides. 
Isoelectric focussing (281 of the J2P-labeIled peptides shown in 
fig.3 was carried out using a Bio-Rad Model 111 Mini IEF Cell 
followed by autoradiography. Lane I, 30.5 min fraction from 
fig.3; lane 2, 31 min fraction; lane 3, 31.5 min fraction; lane 4, 
monophosphorylated site 1 chymotryptic peptide C3 obtained 
by ‘2P-labelling with A-kinase alone [16]; lane 5, mixture of 
peptides Cl + C2 + C3. 
The complete amino acid sequence in this region of 
the G subunit is shown in fig.1. 
shown in fig.1 3.3. Further analysis of the phosphorylation of 
PP-IG by GSK3 
to brief tryptic digestion (see section 2). 90% of the 
32P-radioactivity was released as TCA-soluble pep- 
tides and subsequent reverse phase HPLC revealed 
a major ‘*P-peptide, Tl, which eluted at 25% 
acetonitrile (fig.3B). Tl was further purified by 
rechromatography on the Cis column equilibrated 
in 10 mM ammonium acetate (pH 6.5), and its 
composition is shown in table 1. Sequence analysis 
showed the following primary structure: 
AIFKPGFSPQPS(R). This corresponds to the first 
10 residues of peptide Cl/C2 preceded by three ad- 
ditional residues at the N-terminus. 3*p_ 
radioactivity was present at a stoichiometry of 2. I, 
indicating that Tl was a diphosphorylated 
derivative. Since peptide Tl only contains two of 
the five serines present in peptide Cl/C2, this 
establishes that the first two serines in Cl/C2 are 
the residues phosphorylated by GSK3. The absence 
of significant amounts of a monophosphorylated 
tryptic peptide is explained by more efficient 
phosphorylation in this particular preparation. 
Kinetic analyses howed that after phosphoryla- 
tion by A-kinase, PP-lo and glycogen synthase 
were phosphorylated by GSK3 with apparent K,,, 
values of 0.3-0.5 PM and 2-3 ,uM, respectively, 
which are similar to the intracellular concentra- 
tions of each enzyme [4,5,18]. The V,,, values for 
both substrates were similar. 
Further experiments were carried out to deter- 
mine whether the phosphorylation of site 1, site 2, 
or both sites, by A-kinase was required to promote 
phosphorylation of PP-lo by GSK3. In these ex- 
periments PP-lo was maximally phosphorylated at 
site 1 and site 2, and site 2 was then 
dephosphorylated selectively by using protein 
phosphatase-2A as in [7]. Over 98% of the 32P- 
radioactivity was released from site 2 at a time 
when only 50% of the 32P-radioactivity had been 
released from site 1. Subsequent incubation with 
GSK3 yielded phosphorylation to 50% of the con- 
trol level. These experiments indicate that the ex- 
tent of phosphorylation by GSK3 is determined by 
the amount of phosphate in site 1, and not site 2. 
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4. DISCUSSION 
Glycogen synthase is phosphorylated on nine 
serine residues in vivo [lo], five of which are 
clustered within 17 residues near the C-terminus of 
the molecule. The primary structure of this region 
is: 
1 2 3 4 5 
SVPPSPSLSRHSSPHQSEDEEE [ 191 
The C-terminal serine is phosphorylated by casein 
kinase-2 (CK2) without decreasing activity, while 
phosphorylation of serines 1-4 by GSK3 is accom- 
panied by inactivation (review [18]). It is well 
established that phosphorylation of glycogen syn- 
thase by CK2 is a prerequisite for phosphorylation 
by GSK3 [20,21], and the recent studies of Fiol et 
al. [22] using synthetic peptides corresponding to 
this region have elegantly demonstrated that 
phosphorylation occurs sequentially in an N- 
terminal direction, the phosphorylation of serine-5 
being followed by phosphorylation of serined and 
so on. This suggested that, in this instance, GSK3 
recognises the sequence Ser-X-X-X-Ser(P). 
Although we were unable to detect phosphoryla- 
tion of PP-lo by GSK3 initially [5], our interest in 
this possibility was rekindled by the presence of the 
motif Ser-X-X-X-Ser-X-X-X-Ser immediately N- 
terminal to one of the serines (site 1) 
phosphorylated by A-kinase (fig. 1). The results 
presented in this paper establish that the first two 
serines in this sequence are indeed phosphorylated 
by GSK3, provided that the C-terminal serine (site 
1) is phosphorylated by A-kinase. Nevertheless, 
phosphorylation of these two serines by GSK3 may 
not occur sequentially in an N-terminal direction. 
If this were the case, then peptide C2 (which is 
phosphorylated at only one serine by GSK3) 
should be phosphorylated exclusively at the second 
serine from the N-terminus (fig. 1). However, when 
C2 was subjected to gas phase sequencer analysis 
using the procedure of Wang et al. [23], over half 
of the 32P-radioactivity was associated with the N- 
terminal serine (unpublished). 
In terms of kJK,,, the G subunit of PP-1~ is 
approximately 5-fold more effective as a substrate 
for GSK3 than glycogen synthase, previously the 
best known substrate for this protein kinase [19]. 
Since the serines on glycogen synthase 
phosphorylated by GSK3 are phosphorylated in 
vivo [lo], the G subunit is also likely to be a 
physiological substrate for this protein kinase, and 
the information presented here will facilitate 
analysis of the in vivo phosphorylation states of 
these serine residues. The high level of 
phosphorylation of site 1 in vivo, even in the 
absence of adrenalin (see section l), suggests that 
a protein kinase distinct from A-kinase may 
phosphorylate this serine, allowing GSK3 to 
phosphorylate PP-lo even under basal conditions. 
Besides glycogen synthase, two other proteins 
have been identified where phosphorylation by 
CK2 is required to form the recognition site for 
GSK3, namely the regulatory (Rn) subunit of A- 
kinase [24] and protein phosphatase inhibitor-2 
[25]. The present work is therefore important in 
demonstrating that protein kinases other than CK2 
may be able to synergise with GSK3. This, in turn, 
suggests that more substrates for GSK3 may exist 
than have hitherto been identified. 
While this manuscript was in preparation Fiol et 
al. [26] reported that a synthetic peptide cor- 
responding to residues 4 to 24 of the G subunit se- 
quence (fig.1) is phosphorylated by GSK3 after 
prior phosphorylation by A-kinase. 
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